Acute Porphyria Drug Database

L01CX01 - Trabectedin
Propably not porphyrinogenic
PNP

Rationale
Probably insignificant hepatic exposure. No capacity for CYP-induction or irreversible CYP-inhibition. Side effects such as nausea, anorexia and vomiting may be potentially porphyrinogenic through reduction in caloric intake.
Chemical description
A tetrahydro-isoquinoline originally extracted from the marine tunicate Ectinascidia turbinata, now manufactured synthetically.
Therapeutic characteristics
Trabectedin is a DNA-binding agent used for the treatment of advanced soft-tissue sarcomas. Administered as an intravenous infusion. Common adverse reactions of trabectedin that can be confused with an acute porphyric attack are vomiting, nausea, obstipation, abdominal pain, peripheral neuropathy, paraesthesia and insomnia. Side effects such as nausea, anorexia and vomiting may be potentially porphyrinogenic through reduction in caloric intake.
Hepatic exposure
Therapeutic plasma levels are typically less than 10 nM (EMEA, 2007), therefore hepatic exposure is insignificant.
Metabolism and pharmacokinetics
Trabectedin is oxidatively metabolized primarily by CYP 3A4. Other P450 enzymes may contribute to metabolism. Trabectedin does not induce or inhibit major cytochrome P450 enzymes.

References

  1. Drug reference publications
  2. Sweetman SC, editor. Martindale: The complete drug reference. Trabectedin. Pharmaceutical Press 2009. #1992
  3. Government bodies
  4. EMEA. Trabectedin: scientific discussion. 2007. http://www.ema.europa.eu/humandocs/PDFs/EPAR/yondelis/H-773-en6.pdf. #1990
  5. Summary of Product Characteristics
  6. Norwegian medicines agency. Summary of Product Characteristics (SPC). Yondelis. #1991

Similar drugs
Explore alternative drugs in similar therapeutic classes L01C / L01CX or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙